



**ALAMEDA COUNTY HEALTH CARE SERVICES AGENCY  
PUBLIC HEALTH DEPARTMENT**

Division of Communicable Disease Control & Prevention  
1000 Broadway, 5<sup>th</sup> Floor  
Oakland, CA 94607

**Colleen Chawla, Director**  
**Kimi Watkins-Tartt, Interim Director**

**Erica Pan, MD, MPH, Director**  
Interim Health Officer  
Phone (510) 267-2138  
Fax (510) 268-2140

August 10, 2018

Dear Laboratory Directors:

This letter announces the expansion of current cervical pre-cancer surveillance to also include cervical cancer among Alameda County residents.

Since 2008, ACPHD and the California Department of Public Health (CDPH) have collaborated to conduct cervical pre-cancer surveillance (HPV-Impact) to understand the population-level impact of HPV vaccination. HPV-Impact represents a collaborative effort of state and local health departments, academic institutions, cancer registries, and the Centers for Disease Control and Prevention's Emerging Infections Program at five sites around the nation.

Since September 23, 2013, the Alameda County Public Health Department (ACPHD) has required reporting of high-grade cervical pre-cancers (California Code of Regulations, Title 17, Section 2500). This includes histopathology-confirmed cases of cervical intraepithelial neoplasia (CIN) grades 2 and 3, and adenocarcinoma in-situ (AIS) among women residing in Alameda County.

**Effective January 1, 2018, ACPHD and CDPH have expanded surveillance efforts to include surveillance on cases of cervical cancer in Alameda County residents. Upon request,**

- **CDPH will ask for pathology reports of cervical cancer**
- **CDPH will ask for fixed cervical tissue specimens diagnosed as cervical cancer for HPV typing.**

This minor addition is expected to add minimal burden. Laboratories should continue to report cases of CIN 2, 3, and AIS directly to the California Department of Public Health (CDPH) HPV-Impact Surveillance Unit and cases of cervical cancer to the California Cancer Registry.

Laboratories are requested to report pre-cancer cases using an electronic reporting mechanism; however, cases may be reported in alternate formats. For assistance with reporting, please contact the HPV-Impact Surveillance Unit at (510) 620-2379. Upon request, laboratories are required to send fixed cervical tissue specimens used to diagnose CIN 2, 3, AIS or cervical cancer for HPV typing, per instructions from CDPH HPV-Impact Surveillance Unit. Blocks will be returned to laboratories.

We greatly appreciate the assistance of our laboratory partners in our joint efforts to improve the health of Alameda County residents. For questions about reporting requirements, specimen handling, or for additional information—please visit <http://ceip.us/hpv-impact>. For further questions, please contact Dr. Ina Park, MD, MS at [Ina.Park@ucsf.edu](mailto:Ina.Park@ucsf.edu).

Respectfully,

Erica Pan, MD, MPH  
Interim Health Officer